Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Role of topoisomerase I inhibitors in small-cell lung cancer
S. Shihabi,
C. P. Belani
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Cancer Institute, Next-Generation Therapies
Research output
:
Contribution to journal
›
Review article
›
peer-review
5
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Role of topoisomerase I inhibitors in small-cell lung cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Small Cell Lung Cancer
100%
Topoisomerase Inhibitors
100%
Lung Cancer
66%
United States
33%
New Drugs
33%
Cancer Mortality
33%
Cancer Causes
33%
Active Agent
33%
Overall Response Rate
33%
Relapse Prevention
33%
Irinotecan
33%
Chemosensitive
33%
Durable Response
33%
Further Treatment
33%
Clinical Relapse
33%
Topotecan
33%
Relapsed Disease
33%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Small Cell Lung Cancer
100%
DNA Topoisomerase Inhibitor
100%
Lung Cancer
66%
Malignant Neoplasm
33%
Irinotecan
33%
Medicine and Dentistry
Topoisomerase Inhibitor
100%
Topotecan
33%
Treatment of Small Cell Lung Cancer
33%